Brand VerifiedChina

Tianjin Ringpu Bio-technology Co., Ltd.

Ringpu

Ringpu Biology (Tianjin Ringpu Bio-technology Co., Ltd.) is China's preeminent listed animal health manufacturer and the only Asian-headquartered company in this global Top 10 ranking. Founded in 1998 and headquartered in Tianjin, China, Ringpu generated CNY 3.398 billion (~USD 470 million) in 2025 revenue (up 7.72%), with its pet health segment surging 24.39% to CNY 858 million. Ringpu's defining competitive advantage is its "API-to-endpoint" closed ecosystem: 11 mega-scale production bases housing 94 fully automated production lines with 500+ product approvals, vertically integrated through its affiliate Zhongrui Supply Chain and sister company Ringpai Pet Hospital network directly serving over 14,000 veterinary endpoints nationwide—eliminating distribution layers and maximizing factory utilization.

Strengths:
• Unmatched Manufacturing Scale in Asia: 11 mega-scale production bases, 94 automated production lines, and 500+ veterinary drug approvals—the largest animal health manufacturing footprint in China
• API-to-Endpoint Vertical Integration: In-house API synthesis and biological fermentation eliminates upstream supply chain dependency, enabling aggressive pricing while maintaining margins
• Pet Segment Hypergrowth: CNY 858 million in 2025 companion animal revenue (up 24.39% YoY), driven by domestic feline triple vaccines, canine multivalent vaccines, and long-acting parasiticides
• Direct-to-Clinic Ecosystem: Ringpai Pet Hospital network and Zhongrui Supply Chain collectively serve 14,000+ veterinary endpoints, creating a closed loop from factory to patient
• Regulatory Moat in China: 500+ domestic product approvals create a formidable barrier to entry for foreign competitors seeking Chinese market access
Weaknesses:
• Minimal International Presence: Revenue remains overwhelmingly China-dependent with limited regulatory approvals or brand recognition in North American and European markets
• Brand Premium Gap: Products are positioned as cost-competitive alternatives rather than premium-priced innovations, limiting margin potential in high-value therapeutic categories
• Innovation Depth: Pipeline remains concentrated on vaccines and generics; the company has yet to develop proprietary novel chemical entities or biologics comparable to Western competitors

Business Nature

Ringpu Biology is China's preeminent listed animal health manufacturer, operating 11 mega-scale production bases housing 94 fully automated, high-compliance production lines with over 500 veterinary drug product approvals. The company's defining competitive advantage is its "API-to-formulation" vertical integration strategy—by controlling upstream active pharmaceutical ingredient synthesis and biological fermentation in-house, Ringpu is completely immune to upstream supply chain bottlenecks and can aggressively undercut competitor pricing.

Its pet health segment achieved CNY 858 million in 2025 revenue up 24.39% YoY, driven by domestic feline triple vaccines, canine multivalent vaccines, and long-acting parasiticides. Most critically, Ringpu has built an unparalleled "manufacturing-to-endpoint" closed ecosystem in China: through its affiliate Zhongrui Supply Chain and sister company Ringpai Pet Hospital network, it directly serves over 14,000 veterinary endpoints nationwide—eliminating layers of distributors and maximizing factory utilization.

Core Business Areas

Animal Health Portfolio — Core Business
• Pet Vaccines: feline triple / canine quadrivalent
• Parasiticides: long-acting oral/topical formulations
• Anti-infectives & Anti-inflammatories
• Biologics: avian/swine vaccines
• Diagnostic Kits & Devices
• Feed Additives & Nutritional Supplements
• Disinfectants

Industry Rankings

10Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

10Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Ringpu Biology (Tianjin Ringpu Bio-technology Co., Ltd.) is a China-based listed animal health manufacturer headquartered in Tianjin. Founded in 1998, Ringpu has grown to become China's largest publicly-traded animal health company by manufacturing scale. In 2025, Ringpu generated CNY 3.398 billion (~USD 470 million) in revenue (up 7.72%), with its pet health segment achieving CNY 858 million (up 24.39%), operating 11 mega-scale production bases with 94 automated lines and over 500 product approvals.

Core Business

Ringpu's companion animal portfolio has become the company's primary growth engine, with feline triple vaccines, canine quadrivalent vaccines, and long-acting parasiticides driving 24.39% YoY pet segment growth. The company's "API-to-formulation" vertical integration—controlling upstream pharmaceutical ingredient synthesis and biological fermentation entirely in-house—enables aggressive pricing while maintaining healthy margins. Its 500+ product approvals span vaccines, anti-infectives, parasiticides, diagnostic kits, feed additives, and disinfectants.

Global Presence

While currently China-centric, Ringpu's manufacturing infrastructure is globally significant: 11 mega-scale production bases with 94 high-compliance automated lines represent the largest single-country animal health manufacturing footprint in Asia. The company's unique "manufacturing-to-endpoint" ecosystem—linking its factories through the Zhongrui Supply Chain to the Ringpai Pet Hospital network's 14,000+ veterinary endpoints—creates an unparalleled closed loop that eliminates distributor markups and maximizes factory utilization rates.

Key Strengths

• Largest animal health manufacturing footprint in China with 11 bases, 94 lines, and 500+ approvals
• Pet segment hypergrowth at 24.39% YoY to CNY 858 million in 2025
• API-to-endpoint closed ecosystem serving 14,000+ veterinary endpoints directly
• Vertical integration eliminating upstream supply chain dependencies
• Formidable regulatory barrier with 500+ domestic product approvals

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Tianjin, China

Founded

1998

Employees

1,000+

Factories

11 mega-scale production bases with 94 production lines

Listing

SZSE: 300119

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SZSE: 300119 , Ringpu Official Website
Shenzhen Stock Exchange — Ringpu (300119)
Wikipedia — Ringpu Biology

Back to Rankings